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Oncogenic BRAF induces chronic ER stress condition
resulting in increased basal autophagy and apoptotic
resistance of cutaneous melanoma
M Corazzari*,1,2, F Rapino2, F Ciccosanti2, P Giglio1, M Antonioli2, B Conti2, GM Fimia2,3, PE Lovat4,5 and M Piacentini1,2,5
The notorious unresponsiveness of metastatic cutaneous melanoma to current treatment strategies coupled with its increasing
incidence constitutes a serious worldwide clinical problem. Moreover, despite recent advances in targeted therapies for patients
with BRAFV600E mutant melanomas, acquired resistance remains a limiting factor and hence emphasises the acute need for
comprehensive pre-clinical studies to increase the biological understanding of such tumours in order to develop novel effective
and longlasting therapeutic strategies. Autophagy and ER stress both have a role in melanoma development/progression and
chemoresistance although their real impact is still unclear. Here, we show that BRAFV600E induces a chronic ER stress status
directly increasing basal cell autophagy. BRAFV600E-mediated p38 activation stimulates both the IRE1/ASK1/JNK and TRB3
pathways. Bcl-XL/Bcl-2 phosphorylation by active JNK releases Beclin1 whereas TRB3 inhibits the Akt/mTor axes, together
resulting in an increase in basal autophagy. Furthermore, we demonstrate chemical chaperones relieve the BRAFV600E-mediated
chronic ER stress status, consequently reducing basal autophagic activity and increasing the sensitivity of melanoma cells to
apoptosis. Taken together, these results suggest enhanced basal autophagy, typically observed in BRAFV600E melanomas, is a
consequence of a chronic ER stress status, which ultimately results in the chemoresistance of such tumours. Targeted therapies
that attenuate ER stress may therefore represent a novel and more effective therapeutic strategy for BRAF mutant melanoma.
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Cutaneous melanoma represents one of the most aggressive
and difficult to treat forms of human cancer, with a worldwide
incidence that has steadily increased over the past 40
years.1,2
Notoriously unresponsive to conventional chemotherapy,
metastatic disease is highly invasive and evolves with an
extensive repertoire of molecular defences against immuno-
logical and cytotoxic attack.3
Although linked to exposure to ultraviolet light, it is widely
accepted that both genotypic and phenotypic changes in
melanocytes predispose to melanocyte transformation and
the onset of melanoma.4,5
Surprisingly, p53 mutations are very rare in melanoma, but
activity is, however, impaired through direct or indirect
inactivation of key elements of this pathway, including through
the suppression of APAF-1 expression,6 loss of PTEN
function,7 dysregulation of Bcl-2 expression,8 upregulation of
the anti-apoptotic protein Mcl-1 together with its altered slice
variant expression 9,10 and the ER chaperone GRP78.11–13
Oncogenic mutations, however, in the Ras/Raf pathway are
the most well-described genetic mutations associated with
melanoma development and progression.14 Indeed, up to
90% of all melanomas harbour activating NRAS or BRAF
mutations, with BRAFV600E representing more than 90% of
BRAF mutations,15,16 the consequence of which is the
constitutive activation of RAF-extracellular signal-regulated
kinase/ERK signalling promoting melanoma proliferation and
resistance to apoptosis.17 Nevertheless, mutation of NRAS/
BRAF alone is not sufficient to initiate melanomagenesis,
because these common mutations are also present in
benign nevi, thereby highlighting the requirement of other
factors to drive melanocyte transformation and melanoma
development.15,16 Dysregulation of autophagy has accord-
ingly been postulated as a secondary event contributing to
melanoma progression and, importantly, also has a key role in
chemoresistance.18–20
Autophagy is the principal catabolic process for the bulk
degradation and recycling of aged/damaged cellular compo-
nents, organelles and proteins through the formation of a
double-membraned cytosolic vesicle able to wrap targeted
material. The subsequent fusion with lysosomes and degra-
dation of cargo provide nutrients in times of environmental
stress, such as nutrient deprivation or hypoxia.21 Though
essential for the maintenance of cellular homeostasis
under conditions of nutrient deprivation, paradoxically, auto-
phagy promotes both tumour suppression and tumour
development.22 Although the accumulation of damaged
organelles/cytosolic proteinsmay lead to cellular transformation,
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autophagy may also sustain tumour growth in a microenviron-
ment which is commonly poor of oxygen and nutrients.22 Thus,
not surprisingly, autophagy activation is frequently observed in
late-stage malignancy although the molecular mechanisms
mediating its activation/regain of function remain unclear.
ER stress may also constitute a key secondary event in
melanoma development.23 Primarily a cytoprotective pro-
survival process, ER stress is activated as a result of
accumulated unfolded proteins, protein overload or depletion
of ER calcium stores and mediated through the activity of the
master ER chaperone Grp78 and three signalling pathways;
PERK/eIF2α/ATF4, IRE-1/Xbp-1 and ATF6 which collectively
maintain ER homeostasis through the instigation of an
unfolded protein response (UPR)24 or sustained ER stress
may lead to the induction of apoptosis.25,26 Increasing
evidence indicates that nutrient deprivation and hypoxia lead
to activation of the UPR in various solid tumours, frequently
correlating with resistance to chemotherapy.27 The accepted
hypothesis is thus that activation of the UPR in cancer cells
enables their adaption to such ER stress resulting in the
resistance to apoptosis through the persistent expression of
pro-survival instead of pro-apoptotic proteins.28
Although under stress conditions, autophagy and ER stress
seem to act in parallel, indeed they are closely related,
because one can regulate the other and vice versa. In fact, ER
stress is able to promptly stimulate autophagy,26 whereas
autophagy selectively removes the membranes of the
endoplasmic reticulum at the end of the UPR, although the
molecular mechanisms are still largely unclear.29
In the present study, we investigated the link between
oncogenic BRAFV600E and increased basal autophagy in
melanoma cells, highlighting the pivotal role played by
ER stress, possibly responsible for tumour growth and
chemoresistance.
Results
BRAFV600E increases basal autophagy in melanoma
cells. The deregulation of autophagy is frequent in malig-
nancy, including in cutaneous melanomas. In particular, we
and others have recently demonstrated that melanomas
harbouring mutant BRAFV600E display an increased basal
autophagic rate.3,20,30,31 In order to confirm this observation,
we compared basal autophagic flux in melanoma cell lines,
CHL-1 and A375, with BRAF wild-type (wt) or V600E-
mutated alleles, respectively. As shown in Figure 1a, A375
cells displayed increased expression of lipidated LC3
compared with CHL-1 cells, which was sustained by
co-treatment with bafilomycin A (Baf), to prevent autophagic
flux. To further confirm these observations, analysis of LC3
conversion was also performed in an extended panel of
BRAF wt or mutated melanoma cells (Supplementary Table
1,Figure 1c). Results confirmed an overall increase in basal
autophagy in BRAF mutant compared with BRAF wt cells
(Figure 1c). Moreover, increased basal degradation of the
autophagy cargo p62 was also observed in A375 compared
with CHL-1 cells, as evidenced by the accumulation of this
protein in the presence of Baf (Figure 1b), and confirmed
comparing p62 accumulation in BRAF-mutated versus BRAF
wt melanoma cell lines, in a time-dependent manner
(Figure 1d).
As autophagy is primarily a pro-survival pathway actively
counteracting the apoptotic process, high basal autophagy
levelsmay account for, at least in part, the notorious resistance
of BRAF-mutated melanoma cells to ER stress-induced
apoptosis,17 as confirmed in Figure 1e also showing that
A375 cells are more resistant to thapsigargin-induced
apoptosis, compared with CHL-1 cells.
Oncogenic BRAF results in increased basal autophagy
through chronic ER stress induction. We have previously
shown that BRAF-mutated melanoma cells display reduced
sensitivity to ER stress activation compared with wt cells,
suggesting that an abrogated ER stress response may limit
drug-induced apoptosis in these cells20,32 (Figure 1). We
therefore hypothesised that the reduced ER stress response
observed in BRAF mutant melanoma cells results from
chronic ER stress that desensitizes them to further stress
stimuli.28 To test this hypothesis, we analysed the expression
levels of ER stress markers in our extended panel of
BRAFV600E melanoma cells compared with BRAFWT cells.
As shown in Figure 2a, BRAFV600E melanoma cell lines
displayed approximately twofold greater expression of mRNA
coding for ERdj5, ERp57, ATF4 and Xbp-I33 compared with
BRAF wt cells, indicating that a mild but consistent induction
of ER stress is conferred by an activating mutation in the
BRAF protein kinase.28,32,33
To rule out the possibility that differences in ER stress
induction were due to effects other than BRAF mutation, we
expressed constitutively active BRAFV600E in the BRAFwt SK-
Mel-110 melanoma cell line in order to compare melanoma
cells with identical genetic background except for BRAF
status. Cells stably expressing BRAFV600E or GFP were
selected for more than 1 month in culture, in order to better
represent in vivo tumour development and adaptation to BRAF
activating mutation. Expression of oncogenic BRAF in
SK-Mel-110 cells, as evidenced by ERK1/2 hyper-
phosphorylation (Figure 2c), resulted in a clear upregulation
of mRNA coding for ERp57, ATF4, ERdj5 and Xbp-I
(Figure 2b), increased levels of both calnexin and ERp57
proteins and eIF2α phosphorylation (Figure 2d), as well as
enhanced Xbp-I splicing (Figure 2e), confirming that BRAF
mutation is solely responsible for ER compartment deregula-
tion, and compatible with a chronic ER stress status. These
data thus support recent observations of increased ER stress
as a consequence of BRAF therapy-induced resistance byMa
and co-workers,34 and provide additional insight into the
mechanisms mediating increased basal ER stress in BRAF-
mutated melanoma cells.
Furthermore, overexpression of BRAFV600E also resulted in
increased basal autophagy in SK-Mel-110 cells, as indicated
by both the cytosolic accumulation of p62 puncta (Figure 3a)
and LC3 conversion (Figure 3b), in a time-dependent manner
and under conditions of bafilomycin exposure, suggesting a
correlation between chronic ER stress and increased
basal autophagy in BRAFV600E mutant cells, as previously
evidenced in Figure 1.
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ER stress-mediated JNK activation contributes to basal
autophagy induction. To unveil the possible link connecting
oncogenic BRAF-induced chronic ER stress and the eleva-
tion of basal autophagy, we explored the activation of known
pathways linking these two processes. Results demonstrated
constitutive phosphorylation of JNK in BRAFV600E compared
with BRAF wt cells and normal melanocytes, confirming
protein kinase activation (Figure 4a). To verify whether JNK
activation was specifically due to the presence of oncogenic
BRAF, we analysed JNK phosphorylation in SK-Mel-110 cells
stably expressing BRAFV600E or GFP. As shown in Figure 4c,
phosphorylated JNK is strictly associated with the expression
of mutant BRAF.
ER stress-mediated JNK activation has also been reported
to be associated with the activation of the transmembrane ER
protein IRE1 and subsequent recruitment of cytosolic ASK1
through the adapter molecule TRAF2.35 This multiprotein
complex determines the activation of the kinase ASK1, thus
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Figure 1 Enhanced basal autophagy and less apoptotic responsiveness of BRAFV600E melanoma cells. BRAF wt (CHL-1) and BRAFV600E (A375) melanoma cells were
exposed 3 and 6 h (a) to bafilomycin A (Baf) and basal autophagy was evaluated by monitoring both the LC3 conversion by western blotting analysis (a; Gapdh was used as the
loading control) and p62 accumulation by immunofluorescence (b; bar= 10 μm). Basal autophagy was also evaluated in a panel of BRAFWT or BRAFV600E melanoma cell lines,
in presence or absence of Baf (4 h), by monitoring LC3 conversion by western blotting analysis (c, left panels; Gapdh was used as the loading control). Densitometric analysis of
LC3-II bands is shown in each cell lines, comparing treated with untreated cells (with Baf); mean±S.D. of LC3-II bands in BRAFWT and BRAFV600E cell lines is also reported
(c, right panel). Autophagic flux was quantitated in all melanoma cell lines stably expressing a p62-GFP recombinant protein, treated with Baf in a time-dependent manner, by
cytofluorimetric analysis (d; n= 3). Apoptosis induction was evaluated by cytofluorimetric analysis of propidium iodide-stained CHL-1 and A375 cells exposed 24 h to thapsigargin
(TG, 10 μg/ml; (e; n= 3; P= 0.004)
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mediating the phosphorylation of JNK.35 To verify the
involvement of this pathway in oncogenic BRAF-induced ER
stress-mediated JNK activation, we evaluated the transloca-
tion of TRAF2 onto ER membranes using a subcellular
fractionation assay. Results reported in Figures 4b and d
confirmed a mild but significant relocalization of TRAF2 onto
the ER compartment, as indicated by the colocalization with
the ERmarker calnexin, in cells expressing the mutated BRAF
(see arrows in Figures 4b and d, compare each upper panel
with corresponding bottom panel), consistent with a chronic
rather than an acute ER stress status. Importantly, this
relocalization was specifically induced by BRAFV600E because
GFP-transduced SK-Mel-110 cells exhibited TRAF2 distribu-
tion similar to that observed in CHL-1 cells (see arrows as
marked in Figures 4b and d, upper panels). This evidence was
further confirmed by evaluating the relocalization of TRAF2
G
FP
BR
AF
V6
00
E
Xbp-Iu
s
G
FP
BR
AF
V6
00
E
CLX
ERp57
BR
AF
V6
00
E
P-ERK1/2
BRAF
G
FP
ERK1/2
SK-Mel-110
SK-Mel-110
SK-Mel-110
GFP BRAFV600E GFP BRAFV600E
m
R
N
A
 (r
. l.
)
ERp57 ATF4
GFP BRAFV600E GFP BRAFV600E
m
R
N
A
 (r
. l.
)
ERdj5 Xbp-I
SK-Mel-110 SK-Mel-110
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
eIF2 -P
eIF2
Figure 2 BRAF induces a chronic ER stress status. (a) BRAF-mediated ER stress was evaluated in both BRAFWT and BRAFV600E melanoma cell lines by measuring the
mRNA levels of ER stress markers ERdj5, ERp57, ATF4 and Xbp-1 (spliced, mature form) by qRT-PCR (n= 3). BRAFV600E and GFP were transduced in BRAF wt SK-Mell-110
melanoma cells. BRAF and P-ERK1/2 (ERK1/2 was used as the loading control) protein levels were evaluated by western blotting analysis (c). ER stress status was monitored in
GFP or BRAFV600E expressing cells comparing: (b) mRNA levels of ERp57, ATF4, ERdj5 and Xbp-1 (spliced, mature form) by qRT-PCR (n= 3); (d) protein level of Calnexin
(CLX), ERp57 and eIF2a-P (eIF2a was used as loading control) by western blotting analysis and (e) Xbp-1 mRNA splicing by RT-PCR
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onto ER membranes of other BRAF-mutated cell lines
compared with BRAF wt once (Supplementary Figure S1).
To confirm the role of the IRE-1/TRAF2/ASK1 axes in the
JNK activation and autophagy induction in BRAFV600E cells,
we downregulated the expression of IRE1 using two specific
shRNAs in A375 cells (Figure 4e, left panel) and evaluated the
level of both phosphorylated JNK and LC3 conversion. As
shown in Figure 4e, the impairment of the IRE1 signalling
pathway resulted in decreased JNK activation (upper right
panel) and concomitant reduction of A375 basal autophagy
(bottom right panel). To further confirm these results, A375
cells were treated with SP600125 (10 μM) to inhibit JNK
activation36 prior to analysing of basal autophagic activity, in
the presence or absence of bafilomycin. As shown in Figures
5a–d, inhibiting the activation of JNK resulted in a clear
decrease in basal autophagy, indicating that this pathway
significantly contributes to sustained basal autophagic activity
in BRAF-mutated melanoma cells. These data were also
confirmed in A2058 and SK-Mel-5 cell lines (Supplementary
Figure S2A). To further support these observations, we also
inhibited the activity of JNK by transient overexpression of a
JNK dominant negative (Flag-JNK-DN) into A375 and A2058
cells. As shown in Figure 5e and Supplementary Figure S2B,
expression of JNK-DN clearly resulted in the inhibition of basal
autophagy, as evidenced by reduced LC3 conversion com-
pared with LC3-II expression in control vector transduced
cells (EV).
The known link between JNK and autophagy resides in the
ability of active JNK to phosphorylate the inhibitory partners of
Beclin 1, Bcl-XL and Bcl-2. Phosphorylated Bcl-XL and Bcl-2
are thus released by Beclin 1 enabling its subsequent ability to
stimulate the autophagic process.37,38 To verify the involve-
ment of Bcl-XL in our model, we immunoprecipitated a Flag-
Beclin 1 recombinant protein ectopically expressed in both
GFP and BRAFV600E-expressing SK-Mel-110 cells, and
analysed the presence of Bcl-XL by western blotting. As
shown in Figure 5f, the interaction between Beclin 1 and
Bcl-XL was abrogated in BRAF
V600E cells. On the other hand,
to verify the activity of activated JNK on Bcl-2, we over-
expressed wt or a mutated (T69A S70A S87A) Bcl-2 protein39
in A375 cells and analysed LC3 conversion in the presence or
absence of bafilomycin in a time-course experiment. As
reported in Figure 5g, the presence of mutant Bcl-2 in which
the phosphorylation sites have been mutated inhibited basal
autophagy in A375 cells, compared with Bcl-2 wt expression.
Taken together, these data indicate BRAFV600E-induced ER
stress-mediated constitutive activation of JNK results in the
abrogation of Beclin 1/Bcl-XL and Beclin 1/Bcl-2 inhibitory
interactions leading to constitutive induction of autophagy,
whereas it does not affect the Beclin 1/Mcl-1 inhibitory bond,
which is not regulated by phosphorylation of Mcl-1 (Figure 5f).
ER stress-mediated TRB3 induction contributes to basal
autophagy induction. Our comparative analysis between
wt and BRAF-mutated melanoma cells also evidenced an
altered expression of an additional factor linking ER stress
and autophagy, the mammalian homolog of Drosophila
tribbles TRB3.40 qRT-PCR and western blotting revealed
consistent upregulation of TRB3 at both the mRNA and
protein level in A375 compared with CHL-1 cells (Figure 6a
left and 6b upper panel, respectively). A similar result was
obtained comparing TRB3 expression in GFP- and
BRAFV600E-expressing SK-Mel-110 cells (Figure 6a right
and 6b bottom panel), indicating that TRB3 upregulation
directly correlates with the presence of mutant BRAF.
Moreover, we also confirmed the increased expression of
TRB3 in BRAFV600E compared with BRAF wt cells in an
extended cohort of melanoma cell lines (Supplementary
Figure S3).
As ER stress-induced upregulation of TRB3 induces
autophagy and the inhibition of the Akt/mTORC1 axis,41 we
investigated the contribution of TRB3 to BRAFV600E-induced
basal autophagy. RNAi-mediated knockdown of TRB3 was
carried out in A375 cells (Figure 6c) and the effect on basal
autophagy rate analysed in the presence or absence of
bafilomycin. Similarly to the effects of JNK activity inhibition
previously shown in Figures 4 and 5, our results also
demonstrated that knockdown of TRB3 inhibited BRAFV600E-
induced enhanced basal autophagy (Figures 6d and e, upper
and middle panels).
SK-Mel-110
SK-Mel-110
Figure 3 BRAFV600E expression and basal autophagy. BRAFV600E and GFP or
empty vector (EV) were transduced in BRAF wt SK-Mell-110 melanoma cells. Cells
were incubated with bafilomycin A as indicated, and basal autophagy was evaluated
by both confocal analysis of p62 puncta (a; bar= 10 μm) or LC3 conversion by
western blotting (b; Gapdh was used as the loading control)
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Finally, to determine the effect of dual inhibition of JNK and
TRB3 on oncogenic BRAF-enhanced basal autophagy, we
analysed LC3 conversion (by both western blotting and
immunofluorescence analysis) and p62 degradation in A375
cells in which the JNK or the TRB3 pathways were individually
or collectively abrogated. The concomitant inactivation of both
TRB3 and JNK pathways resulted in significant reduction of
LC3 conversion (Figure 6f), LC3 puncta accumulation
(Figure 6e) and p62 degradation (Figure 6g), indicating an
additive contribution of both signalling pathways to oncogenic
BRAF-induced ER stress-mediated basal autophagy.
p38 activation contributes to BRAF-induced ER stress.
Published data demonstrate that melanoma cells harbouring
hyperactivating mutations in BRAF or NRAS display increased
activation of the stress-activated protein kinase (SAPK)-
p38.42 Moreover, it has also been reported that active p38 in
cancer cells is able to induce an ER stress response to
coordinate cell survival through the activation of PERK and
IRE-1.43
To evaluate the potential role of p38-mediated induction of
chronic ER stress in BRAF mutant melanoma cells, we first
compared the expression of activated p38 (P-p38) in CHL-1
and A375 cells, demonstrating increased P-p38 levels in
BRAF mutated compared with BRAF wt cells (Figure 7a,
upper panel), also confirmed in our cohort of melanoma cell
lines (Supplementary Figure S4 A and B). To unveil the impact
of constitutively activated p38 on melanoma basal autophagy,
we inhibited the activity of p38 by ectopic expression of a p38
dominant negative (p38-DN) into A375 cells prior to evaluating
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Figure 4 Autophagy modulation by the IRE1/TRAF2/JNK axis. JNK activation (P-JNK) was evaluated in primary melanocytes and in a panel of BRAFWT or BRAFV600E
melanoma cell lines (a), or in SK-Mell-110-expressing GFP or BRAFV600E (c) cells by western blotting analysis (JNK was used as loading control). The recruitment of TRAF2 by
activated IRE1 on ER was monitored by western blotting analysis of subcellular fractions from CHL-1 and A375 (b) or SK-Mell-110-expressing GFP or BRAFV600E (d) cells, by
using specific anti-TRAF2 and anti-CLX antibodies; arrows have been used to highlight the different distribution of TRAF2 onto ER membranes, between compared cell lines.
(e) A375 cells were infected with indicated shIRE1- or shCtrl-carrying lentiviruses and IRE1 levels were evaluated by qRT-PCR (right panel; P= 0.0005; n= 3); P-JNK was
evaluated by western blotting analysis (JNK was used as the loading control; upper panel) and LC3 conversion was monitored by western blotting analysis in the presence or
absence of bafilomycin (Baf, 3 h; Gapdh was used as the loading control; bottom panel)
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the effect on LC3 conversion by western blotting. As shown in
Supplementary Figure S4C, the expression of p38-DN
resulted in clear inhibition of basal autophagy in A375 cells.
Secondly, we inhibited the kinase activity of p38 by
treatment of BRAFV600E-mutated A375 cells with 10 μM
SB202190 for 6 or 8 h. As shown in Figure 7, impairment of
p38 activity resulted in: (i) the inhibition of JNK phosphoryla-
tion (Figure 7a, bottom panel), (ii) ER stress response
attenuation (Figure 7b) and (iii) a decrease in basal levels of
autophagy (Figure 7c and Supplementary Figure S4D).
Furthermore, we also inhibited the expression of p38 in
A375 cells by using two specific shRNA oligos (shp38#320
and #472), which, as shown in Figure 7d and Supplementary
Figure S4 (E & F), resulted in the inhibition of p38 expression
as well as decreased expression of ERdj5, ERp57 and TRB3,
JNK phosphorylation and the accumulation of p62. The
inhibition of p38 expression was also carried out in SK-Mel-5
cells by shRNA, and resulted in both TRB3 expression
attenuation and decreased JNK activation (Supplementary
Figure S4G), confirming results obtained in A375 cells.
Collectively, these data suggest p38 signalling contributes
to the induction of a chronic ER stress status in BRAF-mutated
melanoma cells, resulting in an increase in basal autophagic
activity.
Chemical chaperones sensitizes BRAFV600E melanoma
cells to apoptosis induction. Autophagy is primarily
a pro-survival process that is upregulated in advanced stages
of melanoma,3 particularly in those tumours harbouring
hyperactivating mutations in BRAF, to sustain cell
survival and counteract apoptotic signalling induced by
chemotherapeutic agents.3,20,30
The contribution of chronic ER stress to increased basal
autophagy in BRAF-mutated melanoma cells prompted us to
test whether the inhibition of incurred ER stress by chemical
chaperones would lead to a decrease in basal autophagy
and the increased susceptibility to cell death induction.
As 4-phenylbutyric acid (4-PBA) has been shown to reduce
ER stress both in vivo and in vitro,44 we exposed SK-Mel-110
cells expressing BRAFV600E to 4-PBA (3 mM) for 3 weeks and
compared the expression of the ER stress markers ATF4,
ERp57 and TRB3 in either treated or untreated cells. 4-PBA
treatment significantly decreased the expression of all
markers, indicating the relief of ER stress imposed by
BRAFV600E (Figure 7e). In addition, 4-PBA consistently and
significantly reduced basal autophagy in SK-Mel-110
BRAFV600E cells, as evidenced by the reduced conversion
and accumulation of LC3, in presence of bafilomycin
(Figure 7f). These findings therefore indicate that 4-PBA
alleviates chronic ER stress in BRAFV600E mutant melanoma
cells, with consequent reduction in basal autophagic activity.
To determine the effect of 4-PBA-induced reduction of ER
stress and basal autophagy on susceptibility to apoptosis
induction, SK-Mel-110 BRAFV600E cells were subsequently
treated in the presence of absence of a panel of pro-apoptotic
drugs, able to activate different apoptotic pathways; thapsi-
gargin (TG, 10 μg/ml), staurosporine (STS, 0,2 μM) and
doxorubicin (DoxR, 10 μM) (Figure 7g). Results revealed that
4-PBA significantly increased the sensitivity of SK-Mel-110
BRAFV600E cells to drug-induced apoptosis by all agents
tested, thus suggesting chronic ER stress imposed by
oncogenic BRAF expression and the subsequent increase in
basal autophagy represents a skilled pro-survival mechanism
used by these cells to escape cell death induction.
Discussion
It is now quite clear that both autophagy and ER stress have
pivotal roles in cancer development and progression, as well
as response to pharmacological therapeutic intervention.45
Although autophagy may represent a primary barrier to
cellular transformation and the prevention of tumour develop-
ment, paradoxically, both pathways promote pro-survival cell
responses, allowing tumour growth and progression, and
possibly conferring chemoresistance.22,46 Thus, targeting ER
stress and/or autophagy may present considerable benefit for
cancer therapy.47 However, such potential is complicated by
the inter-connection of both processes, and the fact that both
ER stress and autophagy are able to modulate each other and
that their specific function is strictly dependent on both tumour
type and stage progression.45 In cutaneous metastatic
melanoma, we have recently demonstrated the clinical
potential of ER stress-induced apoptosis, with BRAF wt
melanomas showing greater sensitivity, compared with
tumours harbouring hyperactivating mutations in the BRAF
protein kinase.32,33 Moreover, we have also shown (and
confirmed in the present study) that BRAF mutation is
associated with increased levels of basal autophagy.20
Interestingly, ER stress-induced apoptosis is reduced in
melanoma cells harbouring oncogenic BRAF compared with
the observed induction in BRAF wt melanoma cells, and in this
context and in contrast to observations in BRAF mutant
melanoma cells, we have also shown that autophagy inhibition
significantly sensitizes BRAF wt melanoma cells to ER stress-
mediated apoptosis.20 On the basis of established evidence
that: (i) melanoma development and progression is accom-
panied by the induction of ER stress,30 (ii) BRAFV600E
melanomas are characterized by increased rates in basal
autophagy compared with BRAF wt malignancies 20 and that
(iii) ER stress and autophagy are strictly linked,26 we now
show that mutation of BRAF confers a chronic ER stress status
responsible for increased basal autophagy in melanoma cells.
Specifically, the presence of BRAFV600E increases the
expression of typical ER stress markers, compatible with a
chronic ER stress status, possibly accounting for reduced
sensitivity to further ER stress stimulation. Importantly, the
ectopic expression of BRAFV600E mutation not only induced a
chronic ER stress status but was also responsible for
increased basal autophagy. Furthermore, hyperactivation of
BRAF, due to mutation, is directly responsible for p38
activation and subsequent ER stress induction. Moreover,
the IRE1/TRAF2/ASK1/JNK branch of the UPR together with
the TRB3 axis are key to ER-stress-mediated autophagy
induction observed in BRAF-mutated melanoma cells. While
JNK mediates the phosphorylation of both Bcl-XL and Bcl-2,
responsible for Beclin 1 release and autophagy induction,
TRB3, in turn, mediates Akt/mTORC1 inhibition and, thus,
autophagy induction.
Collectively these data demonstrate that oncogenic muta-
tions in BRAF impose a chronic ER stress status within
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melanoma cells, resulting in enhanced basal levels of
autophagy and that the increased activity of these two pro-
survival signalling mechanisms contributes to the notorious
chemoresistance of such tumours (schematically represented
in Figure 7h). Inhibiting ER stress in BRAFmutant melanomas
may thus represent a novel and valuable therapeutic strategy
through which both pro-survival ER stress and autophagy can
be inhibited, and these tumours can be re-sensitized to
chemotherapeutic intervention. Perhaps this approach may
also overcome the potential for tumour recurrence in patients
treated with autophagy inhibitors given autophagy inhibition
per se, may drive secondary tumourigenesis. To our knowl-
edge chemical chaperones are, at present, the only available
molecules able to effectively reduce ER stress both in vitro and
in vivo44 and because in the present study, prolonged 4-PBA
treatment of BRAF-mutated melanoma cells resulted in the
reduced expression of both markers of ER stress and basal
autophagy as well as increased sensitivity to pro-apoptotic
drugs, the clinical use of chemical chaperones may thus
harness ER stress and autophagy modulation for the
therapeutic benefit of patients bearing BRAF V600E tumours.
Recent studies by Ma et al.34 identified ER stress and
autophagy induction as a mechanism mediating resistance to
BRAF inhibitor therapy in patients bearing BRAFV600E mutant
melanomas suggesting a direct link between these two
pathways. Our data thus complement the studies of Ma
et al.34 and provide additional novel molecular insight into
how oncogenic BRAF leads to a chronic ER stress state
and the promotion of basal autophagy. Moreover,
given observations of ER chemical chaperone-mediated
resensitization of BRAFV600E melanoma cells to a panel of
pro-apoptotic drugs, able to activate different apoptotic
pathways, the use of drugs able to harness ER stress or,
alternatively, to target the molecular pathways linking
BRAFV600E-induced ER stress and basal autophagy (such
as the IRE1/TRAF2/ASK1/JNK and the TRB3 axes) for the
clinical benefit of such tumours is warranted. Observations
demonstrating chloroquine/hydroxychloroquine can reduce
tumour immunogenicity,48 and accelerate tumour formation,49
have questioned the benefit of autophagy inhibition in cancer
therapy, and hence our novel proposed therapeutic
approaches (ER stress buffering or JNK and TRB3 axes
targeting) may also increase the sensitivity of BRAF mutant
melanomas to clinical BRAF inhibition.
Materials and Methods
Cell culture and treatments. All cell lines were cultured in DMEM
(Sigma-Aldrich, St. Louis, MO, USA) except for A2058 cells that were cultured in
RPMI (Sigma-Aldrich). Cell culture medium was supplemented with 10% foetal
bovine serum (Sigma-Aldrich), 2 mM L-glutamine (Sigma-Aldrich), 1% penicillin/
streptomycin solution (Sigma-Aldrich) at 37 °C under 5% CO2, except medium.
Primary melanocytes have been previously described.10 Cells were treated with
thapsigargin (Sigma-Aldrich) at a final concentration of 10 μg/ml, staurosporine
(Sigma-Aldrich), 2 μM, doxorubicin (Sigma-Aldrich), 10 μM, Baf (Sigma-Aldrich),
5 nM, 4-PBA (Sigma-Aldrich), 3 mM, SP600125 (Sigma-Aldrich), or 10 μM,
SB202190 (Sigma-Aldrich). All agents were added in DMSO or methanol with an
equal volume of vehicle used to treat control cells (0.1–0.5% DMSO or
methanol).
Retroviral generation and Infection. Fifteen micrograms of retroviral
vectors were co-transfected with 5 μg of expression plasmid for the vesicular
stomatitis virus G protein into the 293 cell line gp/bsr using calcium phosphate.50
Forty-eight hours later, the supernatant containing retroviral particles was recovered
and supplemented with polybrene (4 mg/ml). Cells were infected by incubation with
retroviral containing supernatant for 6–8 h as previously described.50
Lentiviral generation and infection. Ten micrograms of lentiviral vectors
(shRNA-pLKO) were co-transfected with 2.5 μg of an expression plasmid for the
vesicular stomatitis virus G protein and psPAX2 plasmid, containing gag, pol and rev
genes, into the 293T packaging cell line using calcium phosphate as outlined above.
Forty-eight hours later, the supernatant containing the lentiviral particles was
recovered and supplemented with polybrene (4 μg/ml). Cells were infected by
incubation with lentiviral containing supernatant for 6–8 h.
Cell transfection. Expression vectors for BRAFV600E mutant,12 GFP or pcDNA4
(Invitrogen, Carlsbad, CA, USA), wt/mutant Bcl-2,39 JNK-DN 51 and p38-DN 52
(Addgene plasmids 8768, 13340, 13846, 20356, respectively; Cambridge, MA, USA)
vectors were transiently transfected using lipofectamine LTX, according to the
manufacturer’s recommendations.
PCR for XBP-1 splicing. The human XBP-1 sequence was amplified by PCR
using the primer pair AAACAGAGTAGCAGCTCAGACTGC and CCTTCTGGG
TAGACCTCTGGGAG as previously described.33
Quantitative RT-polymerase chain reaction. RNA was extracted by
using Trizol reagent (Invitrogen) as indicated by the supplier. cDNA synthesis was
generated using a reverse transcription kit (Promega, Madison, WI, USA) according
to the manufacturer’s recommendations. Quantitative PCR reactions were
performed with the Rotor-Gene 6000 (Corbett Research Ltd, Cambridgeshire,
UK) thermocycler. Primer sets for all amplicons were designed using the Primer-
Express 1.0 software system (Roche, Basel, Switzerland):
L34 forward: 5′-GTCCCGAACCCCTGGTAATAGA-3′
L34 reverse: 5′-GGCCCTGCTGACATGTTTCTT-3′
ERp57 forward: 5′-TGTGGCATCACGCAGTTTCA-3′
ERp57 reverse: 5′-GGGAAGTTAAAGGGCCACACC-3′
ATF4 forward: 5′-GTGGCCAAGCACTTCAAACC-3′
ATF4 reverse: 5′-CCCGGAGAAGGCATCCTC-3′
ERdj5 forward: 5’-TCATGTTACCACGCTTGGACC-3’
ERdj5 reverse: 5′-GTAAAGCTCGACATGGTGGACAC-3′
Xbp-I (spliced) forward: 5′-GAATGAAGTGAGGCCAGTG-3′
Xbp-I (spliced) reverse: 5′-GAGTCAATACCGCCAGAATC-3′
IRE1 forward: 5′-GAGACCCTGCGCTATCTGACC-3′
IRE1 reverse: 5′-CAGAGTGGCGTCAGCTTG-3′
TRB3 forward: 5′-TCAAGCTGTGTCGCTTTGTCTTCG-3′
TRB3 reverse: 5′-TGCTTGTCCCACAGGGAATCATCT-3′
L34 mRNA level was used as an internal control and results were expressed as
previously described.50
Figure 6 Modulation of TRB3 expression by BRAF. TRB3 expression was evaluated in CHL-1, A375 and SK-Mel-110 cells expressing GFP or BRAFV600E cells by qRT-PCR
(a) and western blotting (b). A375 cells were transiently transfected with specific siRNA oligos and TRB3 downregulation was evaluated by both qRT-PCR and western blotting (c).
Cells were then treated or untreated with bafilomycin and LC3 conversion or p62 puncta accumulation were evaluated by western blotting (d; Gapdh was used as the loading
control) or confocal (e) analysis, respectively. Cells were also treated in the presence or absence of both bafilomycin and SP600125 as indicated, and autophagic rate was
evaluated by measuring the LC3 conversion by western blotting (f; Gapdh was used as the loading control) or by p62 puncta accumulation by confocal microscopy
(e; bar= 10 μm). A375 cells expressing a p62-GFP recombinant protein were transiently transfected with specific siRNA oligos (siCtrl or siTRB3), treated as in (b) and autophagic
flux was evaluated by measuring the levels of p62-GFP by flow cytometry (g; *P= 0.0002; **P= 0.003; n= 3)
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Western blotting. Total proteins were extracted from cells using the Cell Lytic
buffer (Sigma-Aldrich) following addition of protease inhibitors and resolved by
electrophoresis through NuPAGE Bis-Tris gel (Invitrogen) and electroblotted onto
nitrocellulose (Protran, Sigma-Aldrich) membrane. Blots were incubated with indicated
primary antibodies in 5% non-fat dry milk in PBS plus 0.1% Tween20 overnight at 4 °
C. Primary antibodies were: anti-Beclin1 (1 : 500; Becton-Dickinson, Franklin Lakes,
NJ, USA); anti-Gapdh (1 : 106; Calbiochem, Merck Millipore, Darmstadt, Germany);
anti-Flag (1 : 3000; Sigma-Aldrich), BRAF (1 : 500), CLX (1 : 500), TRAF2 (1 : 300)
(Santa Cruz Biotechnology, Dallas, TX, USA); LC3 (1 : 2000), ERK (1 : 2000), P-ERK
(1 : 500), eIF2 (1 : 1000), P-eIF2 (1 : 500), JNK (1 : 1000), P-JNK (1 : 500), p38
(1 : 500), P-p38 (1 : 500) (Cell Signaling Technology, Beverly, MA, USA); ERp57
(1 : 5000, Stressgen, San Diego, CA, USA), Bcl-XL (1 : 300; Enzo Life Sciences,
Farmingdale, NY, USA), Bcl-2 (1 : 500; DAKO, Glostrup, Denmark). Detection was
achieved using horseradish peroxidase-conjugate secondary antibody (1 : 5000;
Jackson ImmunoResearch, Suffolk, UK) and visualized with ECL plus (Amersham
Biosciences, GE Healthcare, Buckinghamshire, UK).
Velocity sedimentation by sucrose gradient. Cells were suspended in
buffer containing 0.25 M sucrose, 10 mM Hepes, and 1 mM EDTA and protease
cocktail inhibitors and homogenized (Sigma-Aldrich) by 100 strokes in a dounce potter
homogenizer and centrifuged for 10 min at 600 × g to obtain a post-nuclear
supernatant. The post-nuclear supernatant was re-centrifuged for 15 min at 11 000 × g
to obtain a post-mitochondrial supernatant. The post-mitochondrial supernatant was
layered onto a discontinuous four-step gradient consisting of 2 ml each of 2.0 M, 1.3 M,
1.0 M and 0.6 M sucrose in 10mM Hepes. Centrifugation was performed using a rotor
(SW41 Ti; Beckman Coulter, High Wycombe, UK) at 27 000 × g for 18 h, and 0.4-ml
fractions were manually collected and checked for density.
IP assay. Cells were suspended in lyses buffer (10 mM Tris-HCl, pH 8.0, 0.5%
NP40,) plus protease and phosphatase inhibitors (protease inhibitor cocktail plus
1 mM sodium fluoride, 1 mM sodium orthovanadate and 1 mM sodium molibdate;
Sigma-Aldrich). One to three milligrams of lysates was incubated at 4 °C for 30 min.
After a centrifugation at 4 °C for 10 min at 13 000 × g to remove insoluble debris,
equal amounts of protein were incubated with 20 μl monoclonal anti-Flag antibody
conjugated with protein A agarose beads (Takara, Otsu, Japan and Sigma-Aldrich,
respectively) with rotation at 4 °C for 4 h followed by 60-min incubation with 30 μl
protein A–Sepharose beads (Roche). The beads were collected by centrifugation
and washed four times with lyses buffer. Proteins bound to the beads were eluted
with 30 μl FLAG-peptide (200 ng/l, Sigma-Aldrich) with rotation at 4 °C for 1 h
followed by a centrifugation at 4 °C for 10 min at 13 000 × g to remove beads. A 2 ×
SDS-PAGE sample buffer was added and samples were boiled at 95 °C for 10 min.
Western blotting analyses were performed as described above.
Apoptosis analysis. Flow cytometry of propidium iodide-stained cells was
used to estimate the level of cell death or apoptosis by measuring the percentage of
cells in the sub-G1 fraction.33
Confocal microscopy. Cells were grown on coverslips and fixed with 4%
PFA in PBS followed by permeabilization with 0.1% Triton X-100 in PBS. p62
primary antibody (1 : 500; MBL, Woburn, MA, USA) was incubated for 1 h at RTand
visualized by means of AlexaFluor-488 (1 : 300, Invitrogen). Coverslips were
mounted in antifade (SlowFade; Invitrogen) and examined under a confocal
microscope (TCS SP2; Leica, Solms, Germany) equipped with a 63 × 1.40–0.60 NA
HCX Plan Apo oil BL objective at RT.
Autophagy assay. Cells infected with a retroviral vector encoding p62-GFP
were seeded at a concentration of 25 × 104 cells/well in 6-well plates and treated as
indicated. Cells were fixed in 4% PFA and fluorescence analysed by FACS analysis
(FacsScan, Becton-Dickinson).
For immunodetection of p62 puncta, cells were grown on coverslips and fixed with
4% PFA in PBS, washed three times and incubated with anti-p62 antibody, as
described above, prior to analysis confocal microscopy. Results were recorded as
percentage of p62-positive cells with p62 punctate as previously described.53 A
minimum of 50–100 cells per sample was counted for triplicate samples per condition
per experiment.
Densitometric analysis. In order to measure protein expression levels,
intensities of specific bands, corresponding to the proteins of interest are measured
using Gel Doc 2000 and QuantyOne software (Bio-Rad, Hercules, CA, USA).
Briefly, blots were acquired using the Gel Doc 2000 apparatus; images were
imported into the QuantyOne software; contrast was adjusted such that the bands
were clearly visible on the blot image; area around each band was selected;
background intensity was subtracted from the blot image; bands were then selected
by drawing a tight boundary around them; intensities of the selected bands was
exported in excel format which was used to perform further analysis; statistical
analysis (t-test) was performed using Prism 5 software (GraphPad, La Jolla, CA,
USA).
Statistical analysis. Unless indicated otherwise, all data are presented as the
means±S.D. of the mean, and statistical differences were evaluated by two-tailed
Student’s t-tests. For all analyses, we considered Po0.05 to be statistically
significant.
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